Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia

International Journal of Cancer

Volumn 119, Issue 4, 2006, Pages 894-900

  Yu, Xue Q ^a   O'Connell, Dianne L ^a   Gibberd, Robert W ^b   Coates, Alan S ^c,d   Armstrong, Bruce K ^d  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Cancer Council Australia   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer registry; Epidemiology; Relative survival; Stage migration; Trend

Indexed keywords

ADULT; AGE; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; REGRESSION ANALYSIS; SEX DIFFERENCE; THYROID CANCER; TREND STUDY; UTERINE CERVIX CANCER; UTERUS CANCER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEW SOUTH WALES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33745877132     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21909     Document Type: Article

References (45)

1. Pui CH. Childhood leukemias. N Engl J Med 1995;332:1618-30.
2. Horwich A, Mason M, Hendry W. Testicular tumours. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology, 2nd ed. New York: Oxford University Press, 2001. 2007-35.
3. Diehl V, Mauch PM, Harris NL. Hodgkin's disease. In: Devita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and pratice of oncology, 6th ed. Philadelphia, USA: Lippincott Williams and Wilkins, 2001. 2339-87.
4. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
5. Kramer BS, Klausner RD. Grappling with cancer-defeatism versus the reality of progress. N Engl J Med 1997;337:931-4.
6. Bailar JC, III, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569-74.
7. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
8. Tracey E, Roder D, Bishop J, Chen S, Chen W. Cancer in New South Wales: incidence and mortality 2003. Sydney: Cancer Institute NSW, 2005.
9. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992;45-173.
10. Supramaniam R, Smith DP, Coates MS, Armstrong BK. Survival from cancer in New South Wales in 1980 to 1995. Sydney: NSW Cancer Council, 1999.
11. Percy C, Van Holten V, Muir CS, eds. International classification of diseases for oncology, 2nd ed. Geneva, Switzerland: World Health Organisation, 1990.
12. Muir CS, Percy C. Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Sci Publ 1991;64-81.
13. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101-21.
14. Chiang CL. Introduction to stochastic processes in biostatistics. New York: John Wiley, 1968.
15. Ederer F, Heise H. Instructions to 1MB 650 programers in processing survival computations. Methodological note No. 10, end results evaluation section. Bethesda, MD: National Cancer Institute, 1959.
16. Yu XQ, O'Connell DL, Gibberd RW, Smith DP, Dickman PW, Armstrong BK. Estimating regional variation in cancer survival: a tool for improving cancer care. Cancer Causes Control 2004;15:611-8.
17. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004;23:51-64.
18. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
19. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72.
20. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43.
21. Kricker A, Farac K, Smith D, Sweeny A, McCredie M, Armstrong B. Breast cancer in New South Wales in 1972-1995: tumour size and the impact of mammographic screening. Int J Cancer 1999;81:877-80.
22. Burton RC, Coates MS, Hersey P, Roberts G. Chetty MP, Chen S, Hayes MH, Howe CG, Armstrong BK. An analysis of a melanoma epidemic. Int J Cancer 1993;55:765-70.
23. Smith DP, Armstrong BK. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 1998;169:17-20.
24. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000;173:403-5.
25. Burgess JR, Dwyer T, McArdle K, Tucker P, Shugg D. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab 2000;85:1513-7.
26. Dickman PW, Hakulinen T, Luostarinen T, Pukkala E, Sankila R, Soderman B, Teppo L. Survival of cancer patients in Finland 1955-1994. Acta Oncol 1999;38(Suppl 12):1-103.
27. Angell-Andersen E, Tretli S, Coleman MP, Langmark F, Grotmol T. Colorectal cancer survival trends in Norway 1958-1997. Eur J Cancer 2004;40:734-42.
28. Du WB, Chia KS, Sankaranarayanan R, Sankila R, Seow A, Lee HP. Population-based survival analysis of colorectal cancer patients in Singapore, 1968-1992. Int J Cancer 2002;99:460-5.
29. Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, Manfredi S, Dancourt V, Faivre J. Colon cancer in France: evidence for improvement in management and survival. Gut 2002;51:60-4.
30. Martijn H, Voogd AC, van de Poll-Franse LV, Repelaer van Driel OJ, Rutten HJ, Coebergh JW. Improved survival of patients with rectal cancer since 1980: a population-based study. Eur J Cancer 2003;39:2073-9.
31. Thomson CS, Brewster DH, Dewar JA, Twelves CJ. Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer 2004;40:743-53.
32. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Click JH. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
33. Armstrong K, O'Connell DL, Leong D, Spigelman AD, Armstrong BK. The New South Wales colorectal cancer care survey, Part 1: surgical management. Sydney: The Cancer Council New South Wales, 2004.
34. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
35. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
36. National Breast Cancer Centre. National survey of women with early breast cancer: their perceptions of care (1997). Sydney: National Breast Cancer Centre, 2004.
37. McEvoy SP, Ingram DM, Byrne MJ, Joseph DJ, Dewar J, Trotter J, Harper C, Haworth C, Harvey JM, Sterrett GF, Jamrozik K, Fritschi L. Breast cancer in Western Australia: clinical practice and clinical guidelines. Med J Aust 2004;181:305-9.
38. Akaza H. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int 2004;93:42-6.
39. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
40. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
41. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute. Based on November 2004 SEER data submission, posted to the SEER website 2005 [accessed July 2005].
42. DeVita VT, Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH, III, Frei E, III, Carbone PP, Canellos GP. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-95.
43. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-93.
44. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ, Jr, Wilson HE. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
45. McCredie M, Stewart J, Smith D, Supramaniam R, Williams S. Observations on the effect of abolishing analgesic abuse and reducing smoking on cancers of the kidney and bladder in New South Wales, Australia, 1972-1995. Cancer Causes Control 1999;10:303-11.